左心通道设备开发商Atraverse完成2940万美元融资，以加速其创新的HOTWIRE™房间隔穿刺通路技术的商业化进程-动脉网

Atraverse Medical Closes $29 Million Financing to Accelerate Commercialization of its Innovative HOTWIRE™ Transseptal Access Technology

CISION 等信源发布 2025-06-10 20:59



可切换为仅中文







Proceeds will be used to grow the commercial organization, scale-up manufacturing operations, and launch additional products in the R&D pipeline.

收益将用于扩大商业组织规模、提升制造业务，并推出研发管道中的其他产品。

SAN DIEGO

圣地亚哥

，

June 10, 2025

2025年6月10日

/PRNewswire/ --

/美通社/ --

Atraverse Medical

穿越医疗

, a medical device company pioneering next-generation transseptal access technology, today announced the close of a

，一家开创下一代经中隔通路技术的医疗器械公司，今天宣布了一项交易的完成

$29.4 million

2940万美元

follow-on financing to accelerate growth. The raise builds upon

后续融资以加速增长。此次融资建立在

$12.5 million

1250万美元

in prior seed investment that was used to obtain FDA 510(k) clearance and begin early commercialization of HOTWIRE™, the company's novel radiofrequency (RF) guidewire for left-heart access. The company has now raised over

在先前的种子投资中，这笔资金被用于获得FDA 510(k)许可，并开始公司创新的左心通路射频（RF）导丝HOTWIRE™的早期商业化。该公司现已筹集超过

$40 million

4000万美元

of investment capital.

投资资本。

Designed to simplify left-heart access through universal sheath compatibility and a zero-exchange workflow, and engineered for enhanced echogenicity and increased rail stiffness, HOTWIRE™ is the focus of the company's current U.S. commercialization strategy.

旨在通过通用鞘兼容性和零交换工作流程简化左心通路，并通过增强回声性和增加轨道刚性进行设计，HOTWIRE™ 是公司当前美国商业化战略的重点。

'This financing is a major milestone for Atraverse and underscores our evolution from a startup company to an emerging growth corporation,' commented John Slump, CEO/President and Co-Founder of Atraverse Medical. 'We're scaling manufacturing, expanding our team, and investing in new product development to build on the HOTWIRE™ platform.

“这笔融资是Atraverse的一个重要里程碑，标志着我们从初创公司向成长型企业的转变，”Atraverse Medical首席执行官/总裁兼联合创始人约翰·斯伦普评论道。“我们正在扩大生产规模，扩充团队，并投资于新产品的开发，以进一步拓展HOTWIRE™平台。”

Our investor syndicate includes angel investors, family offices, and medtech entrepreneurs who share our conviction that HOTWIRE™ is setting a new standard as the future of left-heart access.'.

我们的投资者集团包括天使投资人、家族办公室和医疗技术企业家，他们与我们一样坚信HOTWIRE™正在为左心接入的未来设立新标准。

'The most transformative medical technologies don't just improve procedures—they reimagine entire categories,' said Jean-Luc Pageard, a seasoned entrepreneur, investor, and pioneering innovator of cryoballoon ablation, PFA and other groundbreaking technologies in the electrophysiology and cardiology arena.

“最具变革性的医疗技术不仅仅改进了程序，还重新构想了整个类别，”资深企业家、投资者以及冷冻球囊消融、PFA 和其他在电生理学和心脏病学领域开创性技术的先驱创新者 Jean-Luc Pageard 说道。

'HOTWIRE™ is redefining how physicians approach left-heart access. I invested in Atraverse because the company is developing a scalable, category-shaping innovation that is likely to become the new standard of care for left-heart access.'.

“HOTWIRE™ 正在重新定义医生进行左心通路的方式。我投资了 Atraverse，因为这家公司正在开发一种可扩展的、具有行业塑造能力的创新技术，这项技术有望成为左心通路护理的新标准。”

'HOTWIRE™ delivers clinically significant advantages over existing left-heart access devices, and we are excited to be an early adopter and commercial customer,' commented Dr.

“HOTWIRE™ 相较于现有的左心接入设备具有显著的临床优势，我们很高兴能成为早期采用者和商业客户，”博士评论道。

Vivek Y. Reddy

维韦克·Y·雷迪

, Director of Cardiac Arrhythmia Services at Mount Sinai Hospital,

西奈山医院心律失常服务主任，

New York

纽约

, and co-author on studies regarding the clinical experience of HOTWIRE™.

，并且是关于HOTWIRE™临床经验研究的合著者。

Cleared by the FDA in

已获FDA批准

May 2024

2024年5月

, HOTWIRE™ is approaching its first 1,000 successful procedures across 10 different introducer sheaths as part of a limited market release. The device enables zero-exchange left-heart access and serves as a rail for catheter-based therapies. With universal sheath compatibility, HOTWIRE™ is designed to advance transseptal access technology, optimize procedural workflows, and support improved patient outcomes with a best-in-class platform for left-heart access..

HOTWIRE™ 在有限市场发布期间，即将通过10种不同的导入鞘完成其首1000例成功手术。该设备能够实现无需交换的左心通路，并作为基于导管治疗的轨道。凭借通用的鞘兼容性，HOTWIRE™ 旨在推进经中隔通路技术、优化手术流程，并通过一流的左心通路平台支持改善患者预后。

ABOUT ATRAVERSE MEDICAL

关于ATRAVERSE医疗

Atraverse Medical is a medical device company pioneering next-generation left-heart access and optimized RF technology. The company's proprietary HOTWIRE™ system, featuring universal sheath compatibility, aims to enhance outcomes and streamline workflows for physicians treating cardiovascular disease in millions of patients worldwide.

Atraverse Medical是一家医疗设备公司，致力于开发下一代左心通路和优化的射频技术。该公司专有的HOTWIRE™系统具有通用鞘兼容性，旨在改善全球数百万心血管疾病患者的治疗效果，并简化医生的工作流程。

Based in .

基于。

San Diego, CA

加利福尼亚州圣迭戈

, Atraverse was formed in

，Atraverse 成立于

July 2022

2022年7月

by Dr.

由博士。

Steven Mickelsen